Skip to main content
Cathleen June Park

Cathleen June Park

Health Sciences Assistant Clinical Professor, Step 2, Division of Hematology/Oncology, Chao Family Comprehensive Cancer Center

Biography

Cathleen June Park, M.D., is a Health Sciences Assistant Clinical Professor in the Division of Hematology/Oncology at the Chao Family Comprehensive Cancer Center at the University of California, Irvine. She completed her M.D. at the University of Cincinnati College of Medicine, followed by an Internal Medicine residency at the University of Cincinnati, an Experimental Therapeutics Fellowship at the University of Cincinnati Cancer Center, and a Hematology & Oncology Fellowship at the University of California Davis Cancer Center, where she served as Chief Fellow. Park is board certified in both Medical Oncology and Internal Medicine by the American Board of Internal Medicine.

Park's research focuses on thoracic oncology, particularly non-small cell lung cancer (NSCLC) with targetable mutations such as ALK and EGFR. She has contributed to the development of clinical trial protocols, including a phase I study evaluating receptor-mediated bispecific nano-immunoengineers as a strategy to overcome immunotherapy resistance, and a pilot trial examining locally ablative therapies for patients with oligo-progressive solid tumors. She participated in the ASCO/AACR Workshop on Methods in Clinical Cancer Research in 2023, where she developed a phase I protocol for advanced solid tumors.

Park has authored multiple publications in thoracic oncology and has been an active contributor to the COVID-19 and Cancer Consortium, examining outcomes and disparities in cancer patients during the pandemic. Her recent work includes commentary on ALK tyrosine kinase inhibitors, neoadjuvant osimertinib in resectable EGFR-positive NSCLC, and deuterated targeted therapies. She has presented research at national and international conferences, including ASCO and ESMO meetings, on topics ranging from dose intensity reporting in clinical trials to precision neoadjuvant therapy in resectable NSCLC.

Return to top

Education

  • B.S. in Psychology, University of California San Diego, 2010
  • M.S. in Physiology, University of Cincinnati College of Medicine, 2013
  • M.D., University of Cincinnati College of Medicine, 2017
Return to top

Distinctions

  • ASCO/AACR Workshop on Methods in Clinical Cancer Research, 2023
Return to top

Areas of Expertise

  • Thoracic Oncology
  • Tyrosine Kinase Inhibitor Therapy
  • COVID-19 Cancer Outcomes
  • Carcinoma Unknown Primary
  • Neoadjuvant Osimertinib Treatment
  • Deuterated Drug Development
  • Bispecific Nano-Immunoengager Therapy

Recent Publications

Return to top

Contact Information

Email: cathleep@uci.edu

Return to top

This profile was created with the help of AI.

Last updated on 2/17/2026.